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Background: Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications
that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the
development of IBS symptoms. Aim of this study was therefore to assess the use of PPIs and NSAIDs in patients
with IBS versus controls.
Methods: Cases of IBS from the last 5 years were reviewed. All patients having had at least one prescription for a
particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the time of initial symptom
onset were considered exposed. The control group consisted of individuals randomly selected from the general
population.
Results: 287 cases of IBS were retrieved for analysis together with 287 age and sex-matched controls. Exposure to
PPIs and NSAIDs was significantly higher in IBS patients, whereas no association between ACE inhibitor use and IBS
was found. PPIs were not significantly associated when excluding patients with gastrointestinal reflux disease or
functional dyspepsia. Exposure to SSRIs was also positively associated with IBS, but only when patients with
psychiatric comorbidity were included in the analyses.
Conclusions: Medications that may alter intestinal homeostasis such as NSAIDs and PPIs were more frequently
used in IBS patients compared to controls. This association might be relevant for everyday clinical practice, but it is
remains to be elucidated whether this association is of etiological nature.
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Intestinal permeabilityBackground
Irritable bowel syndrome (IBS) is a condition characte-
rized by recurrent abdominal pain or discomfort accom-
panied by abnormalities in bowel habits [1]. It leads to
considerable morbidity as it is associated with tripling of
missed work-days and doubling of illness-related costs
[1]. National Health Service costs in the UK are 60%
higher in IBS patients than in non-IBS control patients
[2]. As care-seeking behavior can be characteristic for
IBS patients, these patients are also prone to suffer from
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reproduction in any medium, provided the orSince the pathogenesis of IBS is still poorly unders-
tood, the question arises whether the intake of medica-
tion can contribute to or trigger onset of symptoms in
IBS patients, as these patients often utilize medications
that may potentially alter intestinal homeostasis. One
postulated hypothesis points to increased intestinal per-
meability in IBS patients induced by exposure to certain
medication, such as non-steroidal anti-inflammatory drugs
(NSAIDs), thereby allowing luminal antigens to enter the
lamina propria and eliciting an immune and inflammatory
reaction [3]. In particular, proton pump inhibitors (PPIs)
have also been suggested to be involved in the patho-
genesis of IBS, primarily through alteration of intestinal
microbiota composition [4]. PPIs are one of the most
frequently prescribed classes of medication worldwideral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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xicity. In 2009, expenses for omeprazole and esomeprazole
only reached €150 million in the Netherlands [5]. In the
five years since the introduction of esomeprazole in 2001,
prescriptions for PPIs have doubled [6]. With 5 million
prescriptions, omeprazole became the second most fre-
quently prescribed medication in the Netherlands in
2009 [5]. A recent socio-demographic study from the
Netherlands found that 11.8% of the general population
had at least one prescription for a PPI in the year 2006
[7]. It has also been demonstrated that in IBS patients,
the use of PPIs generates an excess health cost of €80
per case per year [8].
We have recently demonstrated that exposure to PPIs
was associated with increased risk for developing micro-
scopic colitis [9], a condition known to share symptoms
and clinical features with IBS [10] and to be associated
with changes in intestinal permeability [11]. PPIs have
not only been demonstrated to be able to alter intestinal
barrier function [12], but also to induce profound changes
in intestinal microbiota composition [13], which in turn
may also lead to secondary changes in epithelial integrity
[14]. It has therefore also been hypothesized that PPIs use
is associated with IBS through causing small intestinal
bacterial overgrowth (SIBO) [4]. Due to these presumed
alterations in intestinal physiology induced by PPI and/or
NSAID use, we postulate that PPIs and NSAIDs may play
an etiological role in the development of IBS. More speci-
fically, we hypothesize that patients with IBS will be more
often exposed to drugs affecting intestinal homeostasis
(PPIs and NSAIDs) at time of presentation with symp-
toms. In this study, we aimed to establish a relationship
between PPI or NSAID use and IBS by comparing expos-
ure these drugs in comparison to control group from the
general population.
Methods
The study was approved by the Medical Ethics Committee
of the Maastricht University Medical Centre+ (MUMC),
Maastricht, the Netherlands (reference number 0904015),
and performed in full accordance with the European
directive 91/507/EEG, and the Declaration of Helsinki
(as amended in Tokyo, Venice, Hong Kong, Somerset
West and Edinburgh. Note of clarification added in
Washington and Tokyo).
Patients
We performed a retrospective, observational, case–con-
trol study at the Division of Gastroenterology-Hepato-
logy at the Maastricht University Medical Center, the
Netherlands, a tertiary and regionally also secondary re-
ferral medical center. Patients presenting with symp-
toms characteristic for IBS who had been referred to
a gastroenterologist at our outpatient clinic by generalpractitioners or other medical specialists for diagnostic
work up and therapy were identified by reviewing medical
records in the period from May 2006 to November 2010.
Symptoms included abdominal pain and discomfort as-
sociated with diarrhea or constipation, bloating and ab-
dominal distension. At the time of the index visit to our
outpatient clinic, the duration of the symptoms was
assessed. In case of patients having had symptoms for at
least 6 months, the diagnosis of IBS was made based on
Rome III criteria at the time of the index visit. In case of
patients having IBS symptoms for less than 6 months,
diagnosis according to Rome III criteria was confirmed
using questionnaires sent to patients to assess symp-
tom duration following initial symptom onset. Only
patients fulfilling Rome III criteria were included in
the investigation.
Written informed consent was obtained from patients
to obtain detailed information of their pharmacy records.
Their medical records were reviewed to assess medical
history and comorbidities. Information on prescribed me-
dication for the period of two years prior to the index visit
was obtained from the pharmacy database. All patients
having had at least one prescription for a period of four
weeks for a PPI (esomeprazole, omeprazole, pantoprazole,
lansoprazole or rabeprazole) in a dose of 20 mg (for lanso-
prazole 15 mg) or more in the 180 days prior to the time
of the initial onset of symptoms were considered exposed
to PPIs. Patients exposed to PPIs only in the period after
initial onset of symptoms were not included in the
analyses. Similarly, we investigated exposure to NSAIDs
(as drugs known to alter intestinal barrier function). The
following doses were considered as minimal drug expos-
ure: diclofenac 12.5 mg, ibuprofen 200 mg, ketoprofen
100 mg, indomethacin 25 mg, aceclofenac 100 mg, nabu-
metone 500 mg, naproxen 250 mg, aspirin 500 mg. COX-
2 inhibitors were not included in the analyses. Also, ex-
posure to selective serotonin reuptake inhibitors (SSRIs,
drugs frequently prescribed to IBS patients) and as control
medication exposure to diuretics and angiotensin convert-
ing enzyme (ACE) inhibitors, drugs that have not been
associated with IBS, was investigated. The rationale for
selecting a time window of 180 days between drug expos-
ure and diagnosis of IBS was the minimum of six months
duration of symptoms needed for IBS diagnosis (Rome III
criteria) and the considerable delay that may occur bet-
ween initial symptom onset and referral with eventual
diagnosis by a gastroenterologist. Psychiatric comorbidity
was defined as evidence of depression or anxiety disorder
in medical history as diagnosed according to the DSM IV.
Controls
The control group consisted of 408 individuals randomly
selected from the general population in Maastricht,
the Netherlands. Residents with a permanent address in
Table 1 Demographic characteristics of irritable bowel
syndrome (IBS) patients and controls
IBS patients N = 287 Controls N = 287 P value
Age (years) 36.7 ± 16 37.4 ± 16 0.64
Gender 75% female 75% female 1.00
BMI (kg/m2) 25.8 ± 3.4 24.7 ± 5.1 0.06
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were selected by a random computerized selection from
the municipality residential register. Controls received
questionnaires regarding their current medical status and
drug exposure. Individuals who self-admitted to being
diagnosed with IBS were excluded. Controls for analyses
(n = 287) were selected from this group and matched to
IBS cases by age (within 1 year) and gender.
Statistical analysis
Statistical analyses were performed using χ2 test to com-
pare gender and comorbidities. Independent Student’s t
test was used to compare age and BMI. Generalized linear
model for binomial regression also adjusted for comorbi-
dities (psychiatric, gastrointestinal reflux disease [GERD],
functional dyspepsia [FD], rheumatoid disorders, fibro-
myalgia) was used to calculate ORs and 95% CIs using
SPSS, version 20.0 (Chicago, IL). Statistical significance
was predetermined as p < 0.05.
Results
During the investigated period, 521 cases were identified
as having IBS according the Rome III criteria. From these,
a total of 287 cases gave informed consent to assess their
pharmacy records. These cases of IBS along with 287 ran-
domly selected age and sex-matched controls were identi-
fied and retrieved for detailed analysis. For demographic











FD or GERD 25.2% 9.8% NA 2.0 [
Psychiatric comorbidity 40.4% 3.5% NA 16.6 [
Fibromyalgia 4.4% 0% NA
Rheumatoid arthritis 6.1% 0% NA
PPIs 21.2% 5.2% 2.2 [1.1-5.0] 2.1 [
NSAIDs 20.55% 3.8% 3.8 [1.7-8.6] 5.2 [2
SSRIs 10.84% 2.1% 3.7 [1.3-10.9] 0.9 [
Diuretics 5.2% 2.8% 1.0 [0.3-3.6] 1.1 [
ACE-I 2.8% 1.4% 1.2 [0.2-4.0] 1.4 [
PPIs = proton pump inhibitors PPIs, NSAIDs = non-steroidal anti-inflammatory drug
converting enzyme inhibitors, RA = rheumatoid arthritis, GERD = gastroesophagealwas as follows: 38% diarrhea-predominant (IBS-D), 30%
constipation-predominant (IBS-C) and 32% mixed sub-
type (IBS-M). A significantly higher numer of IBS had
comorbid conditions (FD or GERD, psychiatric condition,
fibromyalgia, rheumatoid arthritis), compared to controls
(see Table 2, all p < 0.001).
Exposure to PPIs and NSAIDs was significantly higher
in IBS patients (see Table 2). Co-exposure to PPIs and
NSAIDs was also significantly higher in IBS (7.6% vs 0%,
χ2 = 17.4, p < 0.001). Of the patients using NSAIDs
(59/287), 37% also used PPIs at the same time (22/287). See
Table 3 for a summary of the type of PPIs and NSAIDs
patients were exposed to.
IBS patients more frequently used SSRIs (Table 2).
However, no association with SSRI use was found when
correcting for psychiatric comorbidity. When patients
with psychiatric co-morbidity were excluded from analy-
sis, ORs for PPIs, NSAIDs diuretics and ACE inhibitors
remained unchanged, whereas SSRI exposure proved not
to be associated with IBS (Table 2).
No association between ACE inhibitor or diuretic use
and IBS was found (Table 2). No significant association
was found with regards to IBS-subtype (diarrhea, consti-
pation or mixed) and drug exposure.
As PPIs are most frequently prescribed for upper GI
tract complaints originating primarily from FD or GERD,
analyses were repeated with exclusion of patients and
controls with documented comorbid GERD or dyspepsia.
These analyses showed similar ORs for NSAIDs, SSRIs,
diuretics and ACE inhibitors. However, PPI exposure
proved not be associated with the disorder in the group of
IBS patients without comorbid GERD or dyspepsia (OR
2.1 [0.8-5.4]).
Similarly, as NSAIDs are often prescribed for rheumatic
disorders, analyses were also conducted with the exclusion















1.1-3.5] 2.8 [1.5-5.2] 2.1 [1.8-3.8] NA
7.9-34.8] NA 17.0 [8.0-36.2] 33.3 [11.6-95.5]
NA NA NA NA
NA NA NA NA
1.1-4.1] 3.0 [1.3-7.0] 3.1 [1.5-6.2] 2.1 [0.8-5.4]
.5-11.0] 4.1 [1.7-9.6] 5.7 [2.65-12.2] 5.5 [2.3-13.3]
0.3-2.7] 6.3 [0.7-56.8] 0.75 [0.25-2.3] 2.8 [0.5-14.7]
0.3-3.4] 2.4 [0.7-7.9] 1.4 [0.5-3.7] 2.6 [0.8-9.6]
0.3-6.0] 0.9 [0.2-4.4] 1.3 [0.3-5.2] 0.8 [0.1-5.0]
s, SSRIs = selective serotonin reuptake inhibitors, ACE-I = angiotensin-
reflux disease, FD = functional dyspepsia. NA = not applicable.
Table 3 Types of drugs used by irritable bowel syndrome
patients
Type of PPI1 Type of NSAID2
Pantoprazole 44.0% Diclofenac 47.0%
Omeprazole 28.8% Ibuprofen 41.2%
Esomeprazole 27.1% Naproxen 21.6%
Rabeprazole 6.7% Aceclofenac 3.9%
1 6 patients used multiple PPIs.
2 7 patients used multiple NSAIDs.
PPI = proton pump inhibitor. NSAID = non-steroidal anti-inflammatory drug.
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lysis with the inclusion of all subjects.
Discussion
In this study, we found that a significantly higher num-
ber of IBS patients use certain medications that can po-
tentially alter intestinal homeostasis, such as PPIs and
NSAIDs, in comparison to controls. Medication use of
patients was examined in the period preceding the time
of presentation at our clinic with their IBS symptoms, ai-
ming to establish a temporal relationship between medica-
tion use and onset of symptoms.
We here demonstrate in our study population of IBS
patients a positive association with IBS and exposure to
PPIs and NSAIDs, but also to SSRIs. The former two are
associated with alterations of intestinal physiology, where-
as the latter is often prescribed in IBS due to concomitant
psychiatric comorbidity. In order to delineate between a
potential causal effect and mere therapeutic utilization of
these drugs, we conducted analysis with the exclusion of
IBS patients with certain comorbid conditions. For ins-
tance, IBS patients often suffer from functional dyspepsia;
the degree of overlap varies between 15 and 42% [15,16].
Because patients with IBS are more likely to have GERD
and dyspepsia in comparison to controls, they are also
more likely to receive PPI therapy. Therefore, following
initial analyses, we conducted additional analyses exclud-
ing the cases and controls exposed to PPIs due to therapy
for concomitant upper GI complaints based on functional
dyspepsia or GERD. In this case, PPI exposure was not
associated with IBS. We therefore presume that the expo-
sure to PPIs can be explained by the therapeutic use of
PPIs for upper GI complaints.
We also found a positive association with the exposure
to NSAIDs, reproducing previous literature findings [17].
Pain-related symptoms of extragastrointestinal origin fre-
quently observed in IBS could be the explanation for the
increased use of NSAIDs in this population [18]. More-
over, as IBS patients tend to suffer from recurring and
therapy-refractory abdominal pain, overuse of NSAIDs in
IBS patients can be extremely common in everyday clini-
cal practice. Therefore, despite the fact that NSAIDs areknown to alter intestinal physiology [19] and in particular
barrier function, previous studies suggest that the associa-
tion with NSAIDs is due to the tendency of patients with
IBS having pain complaints rather than analgesics being a
causative factor [17]. We therefore conducted analyses
with the exclusion of subjects with rheumatoid disorders,
as a common source of extragastrointestinal pain. Results
of these analyses still showed a significant association bet-
ween NSAIDs use and IBS. This could be explained by the
fact that patients were taking NSAIDs due to pain symp-
toms related to conditions other than rheumatoid disor-
ders. On the other hand, recent findings have shown that
NSAIDs can compromise intestinal permeability in IBS
patients to a greater extent than in healthy subjects [3].
Furthermore, another epidemiological study demonstrated
that IBS patients using NSAIDs were also more likely to
have persistent irritable bowel syndrome [20]. This ap-
pears to be in line with the hypothesis that NSAID therapy
affects intestinal permeability resulting in sustained low-
grade mucosal inflammation [21]. This implies that even
if NSAIDs do not necessarily trigger IBS symptoms,
they may be able to sustain the condition by altering intes-
tinal physiology and in particular by impairing intestinal
permeability.
PPIs and NSAIDs are often used simultaneously, with
the former frequently co-prescribed to reduce gastrointes-
tinal injury due to the latter. In our study, over a third of
the patients using NSAIDs also used PPIs – presumably
for gastroprotection. Recent video capsule studies suggest
[22,23] a very high incidence (55-70%) of intestinal dam-
age in healthy humans taking both NSAIDs and PPIs for
2 weeks. A more recent study performed in rats demon-
strated that PPIs lead to a marked exacerbation of small
intestinal ulceration induced by NSAIDs, which was trans-
ferable to germ-free mice via microbiota isolated from the
PPI-treated rats. This observation points to an important
role for microbial alterations. When PPIs were adminis-
tered alone, significant changes in intestinal microbiota
were observed, with 80% reduction in the levels of the
beneficial Bifidobacteria spp, whereas little effect was de-
tected on the morphology of the intestinal mucosa [24].
It is generally accepted that PPI therapy can alter in-
testinal microbial profiles by inducing hypochlorhydria
resulting in a diminished host defense against certain bac-
teria [25-28]. A recent study by Lombardo et al. indeed
suggested that PPI therapy in humans may potentially re-
sult in small intestinal bacterial overgrowth (SIBO) [13]. It
is not known whether the changes in intestinal microbiota
induced by PPI therapy contribute to the development of
symptoms and clinical conditions such as IBS [29]. In ano-
ther recent study using duodenal aspirates, no clear asso-
ciation was found between SIBO with IBS or PPI use [30].
It therefore still remains unclear whether SIBO, if at all
present in IBS, is a cause or merely an epiphenomenon of
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sole explanation for symptom development in IBS [29].
Overall, it is tempting to assume that PPIs can potentially
induce alterations in intestinal microbiota, albeit not to a
clinically significant degree, which can in turn impair the
capacity of the intestine to respond to noxious agents,
such as NSAIDs. Such ‘two-hit’ theory could provide an
explanation for the relevance of co-exposure to PPIs and
NSAIDs in the onset of IBS symptoms [31].
Besides PPIs and NSAIDs, the use of SSRIs was also
associated with IBS in our study, but only when patients
with psychiatric comorbidity were included in the ana-
lyses. Excluding IBS patients with psychiatric comorbid-
ities from the analyses, accounting for 38% of our study
population, resulted in a loss of positive association with
exposure to SSRIs. This may be due to the high preva-
lence of psychiatric comorbidities in this population for
which IBS patients receive SSRI therapy. This observa-
tion therefore suggests that the association of IBS and
SSRI use is probably due to the therapeutic application
of SSRIs for preexistent psychiatric conditions. Although
no data were available on the duration of psychiatric co-
morbid conditions, we postulate that these may have been
present prior to the onset of the gastrointestinal symp-
toms and are therefore less likely to be involved in trigge-
ring IBS symptoms.
Although we were able to demonstrate a positive asso-
ciation with IBS and the use of drugs known to alter in-
testinal physiology, our study is hypothesis generating
rather than proving an etiological relationship due to a
number of limitations. While it is apparent that IBS pa-
tients utilize medication more often than controls, case–
control studies generally do not allow interpretation with
respect to a causal relation. In an attempt to establish a
temporal relationship, we aimed to assess exposure to
medication prior to onset of symptoms, implicating that
this exposure can potentially trigger symptoms characte-
ristic for IBS. However, we were not able to report on
exact symptom history in the 180-day period investigated
for drug exposure in relation to drug intake, which hin-
ders the establishment of a true cause-effect relationship.
We were also unable to report on a potential relationship
between drug use and the severity of IBS-related symp-
toms. Furthermore, we could not take into account the
use of over-the-counter medication. Also, our patient po-
pulation is possibly a selected population consisting of pa-
tient presenting to our secondary/tertiary referral, which
may not represent the IBS population as a whole.
Conclusion
Our case–control study points to an increased use of
certain drugs prior to consultation for symptoms in IBS
patients, in particular PPIs and NSAIDs. Both PPIs and
NSAIDs are frequently prescribed drugs and IBS patientsare prone to over-utilize drugs. Therefore, one should be
aware that prescribing PPIs for upper GI complaints or
NSAIDs for pain relief may potentially trigger mecha-
nisms resulting in symptom generation representative for
IBS. Animal data suggest that the combination of PPIs
and NSAIDs, in particular, is able to induce profound al-
terations in intestinal homeostasis. As case–control stu-
dies generally do not allow interpretation of a cause-effect
relationship, further research should include prospective
evaluation of PPI users and NSAIDs users monitoring the
development of IBS-symptoms in relation to drug expo-
sure to ascertain whether this increased exposure to PPIs
and NSAIDs should be considered as legitimate etiological
factors in IBS.Abbreviations
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